These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37079495)

  • 1. Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising.
    Sullivan HW; O'Donoghue AC; Boudewyns V; Paquin RS; Ferriola-Bruckenstein K
    Oncologist; 2023 Jul; 28(7):e542-e553. PubMed ID: 37079495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious and actionable risks, plus disclosure: Investigating an alternative approach for presenting risk information in prescription drug television advertisements.
    Betts KR; Boudewyns V; Aikin KJ; Squire C; Dolina S; Hayes JJ; Southwell BG
    Res Social Adm Pharm; 2018 Oct; 14(10):951-963. PubMed ID: 28844621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of misleading information in prescription drug television advertising: The roles of advertisement similarity and time delay.
    Aikin KJ; Southwell BG; Paquin RS; Rupert DJ; O'Donoghue AC; Betts KR; Lee PK
    Res Social Adm Pharm; 2017; 13(2):378-388. PubMed ID: 27178746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Including Quantitative Information on Multiple Endpoints in Direct-to-Consumer Prescription Drug Television Advertisements.
    Sullivan HW; O'Donoghue AC; Lynch M; Johnson M; Davis C; Rupert DJ
    Med Decis Making; 2019 Nov; 39(8):975-985. PubMed ID: 31583947
    [No Abstract]   [Full Text] [Related]  

  • 5. Attention to price disclosures in direct-to-consumer prescription drug advertising and the impact on drug perceptions.
    Ball JG; Hollin IL
    Res Social Adm Pharm; 2022 Aug; 18(8):3402-3413. PubMed ID: 34819265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consumer responses to framing statements preceding the major risk statement in prescription drug DTC TV ads.
    Aikin KJ; Betts KR; Boudewyns V; Johnson M; Davis CN
    Res Social Adm Pharm; 2020 Sep; 16(9):1237-1247. PubMed ID: 31838056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual presentations of efficacy data in direct-to-consumer prescription drug print and television advertisements: A randomized study.
    Sullivan HW; O'Donoghue AC; Aikin KJ; Chowdhury D; Moultrie RR; Rupert DJ
    Patient Educ Couns; 2016 May; 99(5):790-9. PubMed ID: 26749356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visual images of prescription drug benefits in direct-to-consumer television advertisements.
    Sullivan HW; O'Donoghue AC; Lynch M; Johnson M; Davis C; Amoozegar JB; Rupert DJ
    Patient Educ Couns; 2021 Sep; 104(9):2240-2249. PubMed ID: 33618970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs.
    Faerber AE; Kreling DH
    J Gen Intern Med; 2014 Jan; 29(1):110-8. PubMed ID: 24030427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of comparative claims in prescription drug direct-to-consumer advertising on consumer perceptions and recall.
    O'Donoghue AC; Williams PA; Sullivan HW; Boudewyns V; Squire C; Willoughby JF
    Soc Sci Med; 2014 Nov; 120():1-11. PubMed ID: 25194471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion.
    Boudewyns V; O'Donoghue AC; Paquin RS; Aikin KJ; Ferriola-Bruckenstein K; Scott VM
    Oncologist; 2021 Dec; 26(12):1071-1078. PubMed ID: 34510619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs.
    Applequist J; Ball JG
    Ann Fam Med; 2018 May; 16(3):211-216. PubMed ID: 29760024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Direct-to-Consumer Advertising of Prescription Drugs With Consumer Health-Related Intentions and Beliefs Among Individuals at Risk of Cardiovascular Disease.
    Eisenberg MD; Singh Y; Sood N
    JAMA Health Forum; 2022 Aug; 3(8):e222570. PubMed ID: 36200632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Affiliation Disclosure and Control Over User-Generated Comments Affects Consumer Health Knowledge and Behavior: A Randomized Controlled Experiment of Pharmaceutical Direct-to-Consumer Advertising on Social Media.
    DeAndrea DC; Vendemia MA
    J Med Internet Res; 2016 Jul; 18(7):e189. PubMed ID: 27435883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
    Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
    J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of exposure of youths at risk for smoking to television advertising for nicotine replacement therapy and Zyban: an experimental study.
    Wakefield M; Durrant R
    Health Commun; 2006; 19(3):253-8. PubMed ID: 16719728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fair Balance and Adequate Provision in Direct-to-Consumer Prescription Drug Online Banner Advertisements: A Content Analysis.
    Adams C
    J Med Internet Res; 2016 Feb; 18(2):e33. PubMed ID: 26892749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.
    Hu C; Wang M; Wu C; Zhou H; Chen C; Diede S
    JAMA Netw Open; 2021 May; 4(5):e218175. PubMed ID: 34047794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presenting efficacy information in direct-to-consumer prescription drug advertisements.
    O'Donoghue AC; Sullivan HW; Aikin KJ; Chowdhury D; Moultrie RR; Rupert DJ
    Patient Educ Couns; 2014 May; 95(2):271-80. PubMed ID: 24581929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.